Anavex Life Sciences Stock News

Morgan Stanley increased its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 218.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 271,673 shares of the biotechnology companys stock after purchasing an additional 186,329 shares during the quarter. Morgan Stanley owned []

AVXL earnings call for the period ending September 30, 2021.

Anavex Life Sciences Corp. (NASDAQ:AVXL) has a beta value of 0.61 and has seen 2.19 million shares traded in the last trading session. The company, currently valued at $1.46B, closed the last trade at $19.40 per share which meant it lost -$1.04 on the day or -5.09% during that session. The AVXL stock price is Anavex Life Sciences Corp. (AVXL): Why Is The Stock Strong? Read More »

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therap

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, is scheduled to participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021 at 12:10 p.m. ET.

NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeu

BTIG Research reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note issued to investors on Thursday morning, Price Targets.com reports. BTIG Research currently has a $34.00 price objective on the biotechnology companys stock. AVXL has been the subject of several other reports. Zacks Investment Research upgraded Anavex Life Sciences []

Goldman Sachs Group Inc. cut its position in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 33.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 90,117 shares of the biotechnology companys stock after selling 45,755 shares during the period. Goldman Sachs Group Inc. owned about 0.13% []

Anavex Life Sciences (NASDAQ:AVXL)s stock had its buy rating reissued by investment analysts at BTIG Research in a note issued to investors on Thursday, Price Targets.com reports. They presently have a $34.00 price target on the biotechnology companys stock. BTIG Researchs target price suggests a potential upside of 74.81% from the companys current price. AVXL [] The post Anavex Life Sciences (NASDAQ:AVXL) Stock Rating Reaffirmed by BTIG Research appeared first on ETF Daily News .

Anavex Life Sciences (NASDAQ:AVXL) issued its quarterly earnings data on Wednesday. The biotechnology company reported ($0.15) earnings per share for the quarter, meeting the consensus estimate of ($0.15), Yahoo Finance reports. During the same period in the prior year, the firm earned ($0.10) EPS. AVXL traded up $0.46 during trading hours on Friday, hitting $19.45. []

Anavex Life Sciences Corp. (NASDAQ:AVXL) gapped up before the market opened on Wednesday . The stock had previously closed at $17.97, but opened at $19.33. Anavex Life Sciences shares last traded at $18.32, with a volume of 5,125 shares trading hands. A number of equities analysts have weighed in on AVXL shares. HC Wainwright reiterated []

On Wednesday, Anavex Life Sciences Corp (NASDAQ:AVXL) shares rallied 5.68% after reporting its most recent annual results. The company announced its full-year 2021 results before markets opened, match

On Wednesday, Anavex Life Sciences Corp (NASDAQ:AVXL) shares rallied 5.68% after reporting its most recent annual results. The company announced its full-year 2021 results before markets opened, matching the consensus expectations on earnings. Anavex Life Sciences posted FY2021 GAAP earnings per share of -$0.54, in line with expectations. On the other hand, its FQE EPS […] The post Is it safe to buy Anavex shares after matching earnings expectations? appeared first on Invezz.

Anavex Life Sciences Corp (NASDAQ:AVXL) stock rose 5.68% (As on Nov 25, 7:56:06 AM UTC-4, Source: Google Finance) after the company in the third quarter The post Anavex Life Sciences Corp (NASDAQ:AVXL) executed full enrollment of three Precision Medicine clinical trials appeared first on FXDailyReport.Com .

On Wednesday, Anavex Life Sciences Corp (NASDAQ:AVXL) shares rallied 5.68% after reporting its most recent annual results. The company announced its full-year 2021 results before markets opened, match